Lee, Danner & Bass’s GSK GSK Stock Holding History

Lee, Danner & Bass’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,144	Closed	-$38.7K	–	420
2024 Q4	$38.7K	Buy	+1,144	New	+$41.2K	﹤0.01%	375

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lee, Danner & Bass's GSK Position: Q1 2025 in Review

Lee, Danner & Bass sold out of GSK (GSK) in Q1 2025, closing a stake of 1,144 shares — an estimated $38.7K sold.

Lee, Danner & Bass first reported a position in GSK in Q4 2024 and held it in 1 quarter. The position peaked at $38.7K in Q4 2024. 857 funds tracked by Wall St. Rank hold GSK as of Q1 2025.

Lee, Danner & Bass reported no remaining GSK position as of Q1 2025 after selling out during the quarter.
Lee, Danner & Bass sold 1,144 GSK shares in Q1 2025, an estimated $38.7K.
Lee, Danner & Bass first reported a position in GSK in Q4 2024 and held it in 1 quarter.
Lee, Danner & Bass's GSK position peaked at $38.7K in Q4 2024.
857 funds tracked by Wall St. Rank held GSK as of Q1 2025.

Based on Lee, Danner & Bass's 13F filing for Q1 2025, filed 29 Apr 2025.